LJPC - La Jolla Pharmaceutical Company
8.30 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 8.75 |
| Open | 8.80 |
| Bid | 8.31 x 1200 |
| Ask | 8.32 x 1300 |
| Day's Range | 8.16 - 8.81 |
| 52 Week Range | 5.01 - 38.39 |
| Volume | 658,560 |
| Avg. Volume | 1,274,528 |
| Market Cap | 224.92M |
| Beta (3Y Monthly) | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.82 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.50 |
- Zacks•13 days ago
Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.
- Motley Fool•17 days ago
Here's Why La Jolla Pharmaceutical Has More Than Doubled Over the Last 2 Days
A mid-stage clinical trial has investors excited about the biotech's future.
- GlobeNewswire•18 days ago
La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced positive results from the pre-specified interim analysis of its Phase 2 study of LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis (HH).
- Simply Wall St.•last month
How La Jolla Pharmaceutical Company (NASDAQ:LJPC) Can Impact Your Portfolio Volatility
If you own shares in La Jolla Pharmaceutical Company (NASDAQ:LJPC) then it's worth thinking about how it contributes...
- Zacks•2 months ago
La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Misses Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
La Jolla Pharmaceutical: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of $1.17. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
SAN DIEGO, May 06, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Zacks•2 months ago
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GuruFocus.com•2 months agoConsider These 3 Falling Knives
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is not uncommon among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NCSM. The closing price on Friday was 4.1% off the 52-week low of $3.93 and 355% from the 52-week high of $18.6.
- GlobeNewswire•2 months ago
La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the New Investigational Drug Product, LJPC-0118, for the treatment of severe malaria. The Breakthrough Therapy designation is an FDA program designed to expedite the development and review of drugs that are intended to treat serious or life-threatening conditions.
- GlobeNewswire•3 months ago
La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Darryl Wellinghoff as Chief Commercial Officer. “We are excited to welcome Darryl to La Jolla’s leadership team,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer. “Darryl brings extensive and highly relevant experience and depth of knowledge in sales, marketing, product launch and market access gained as a result of many successful product launches.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of LJPC earnings conference call or presentation 4-Mar-19 9:30pm GMT
Q4 2018 La Jolla Pharmaceutical Co Earnings Call
- GlobeNewswire•4 months ago
La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
SAN DIEGO, March 07, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Simply Wall St.•4 months ago
Does La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) CEO Pay Reflect Performance?
In 2012 George Tidmarsh was appointed CEO of La Jolla Pharmaceutical Company (NASDAQ:LJPC). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
- Zacks•4 months ago
Do Options Traders Know Something About La Jolla Pharmaceutical (LJPC) Stock We Don't?
Investors need to pay close attention to La Jolla Pharmaceutical (LJPC) stock based on the movements in the options market lately.
- Benzinga•4 months ago
The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 4) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
Motley Fool•4 months agoLa Jolla Pharmaceutical Co (LJPC) Q4 2018 Earnings Conference Call Transcript
LJPC earnings call for the period ending December 31, 2018.
- GlobeNewswire•4 months ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives
SAN DIEGO, March 04, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- GlobeNewswire•4 months ago
La Jolla Pharmaceutical Company to Release Fourth Quarter and Full Year 2018 Financial Results on March 4, 2019
SAN DIEGO, Feb. 25, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- GlobeNewswire•4 months ago
La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress
SAN DIEGO, Feb. 14, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that there will be multiple presentations on GIAPREZA (angiotensin II) at the Society.
- GlobeNewswire•5 months ago
Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•5 months ago
Biotech Companies to Watch
HENDERSON, NV / ACCESSWIRE / January 10, 2019 / Biotech has started 2019 off with a bang. Below are a few that you should be paying attention to. One that looks poised for a big year, Delcath Systems, ...
- Benzinga•5 months ago
HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance
La Jolla Pharmaceutical Company (NASDAQ: LJPC ) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million ...
- Motley Fool•5 months ago
Here's Why La Jolla Pharmaceutical Tumbled Today
The company provided preliminary operating results for 2018 and expectations for the year ahead.
